Perspective Therapeutics, Inc. ( CATX ) Giełda Amerykańska

Cena: 4.08 ( 8.07% )

Aktualizacja 07-10 21:58
Giełda Amerykańska
Branża: Medical - Devices

Notowania:


Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 116
Giełda: Giełda Amerykańska
Ilość akcji w obrocie: 73%
Ilość akcji: 493 313 000
Debiut giełdowy: 2005-11-10
WWW: https://www.perspectivetherapeutics.com
CEO: Mr. Johan M. Spoor
Adres: 350 Hills Street
Siedziba: 99354 Richland
ISIN: US46489V1044
Opis firmy:

Perspective Therapeutics, Inc., wraz ze swoimi spółkami zależnymi, rozwija, produkuje, sprzedaje i rynkowe produkty medyczne oparte na izotopach do leczenia raka i innych chorób złośliwych w Stanach Zjednoczonych i na arenie międzynarodowej. Firma oferuje nasiona brachyterapii Ces-1 Cesium-131 ​​do leczenia raka prostaty, mózgu, płuc, głowy i szyi, ginekologicznego, miednicy/brzucha i jelita grubego. Sprzedaje swoje produkty do obiektów lub praktyk lekarzy, które wykorzystują różne obiekty chirurgiczne. Firma była wcześniej znana jako Isoray, Inc. i zmieniła nazwę na perspektywa Therapeutics, Inc. w lutym 2022 r. Perspective Therapeutics, Inc. została założona w 1998 roku i ma siedzibę w Richland w stanie Waszyngton.

Wskaźniki finansowe
Kapitalizacja (USD) 303 222 606
Aktywa: 391 153 000
Cena: 4.08
Wskaźnik Altman Z-Score: 1.7
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -3.3
Ilość akcji w obrocie: 73%
Średni wolumen: 1 295 078
Ilość akcji 74 228 300
Wskaźniki finansowe
Przychody TTM 337 000
Zobowiązania: 62 682 000
Przedział 52 tyg.: 1.6 - 16.55
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -1.2
P/E branży: 26.8
Beta: 1.467
Raport okresowy: 2025-08-12
WWW: https://www.perspectivetherapeutics.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Jonathan R. Hunt Chief Financial Officer & Co-Principal Financial Officer 944 354 1967
Mr. Johan M. Spoor Chief Executive Officer & Director 855 781 1972
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer 633 140 1966
Mr. Amos Hedt BA, PGradDip Chief Business Strategy Officer 0 0
Mr. Mark J. Austin CPA Vice President of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary 0 1987
Mr. Shane Cobb Executive Vice President of Operations 0 0
Dr. Michael K. Schultz Ph.D. Chief Science Officer 0 0
Mr. Andrew Bright Executive Vice President of Brachytherapy 0 0
Dr. Frances L. Johnson M.D. Chief Innovation Officer 0 0
Mr. David Hauser Ph.D. Senior Vice President of Clinical Operations 0 0
Wiadomości dla Perspective Therapeutics, Inc.
Tytuł Treść Źródło Aktualizacja Link
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2025. globenewswire.com 2025-05-12 20:36:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Participate in Upcoming May Investor Conferences SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com 2025-05-01 11:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company's [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO plans to release further details for regular abstracts on May 22, 2025 at 5:00 PM EDT. globenewswire.com 2025-04-23 16:25:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 12, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. globenewswire.com 2025-04-17 11:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), as monotherapy in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. globenewswire.com 2025-04-11 11:00:00 Czytaj oryginał (ang.)
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com 2025-04-02 14:35:34 Czytaj oryginał (ang.)
Perspective Therapeutics to Participate in Upcoming April Investor Conferences SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com 2025-03-31 11:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2024. globenewswire.com 2025-03-26 18:10:00 Czytaj oryginał (ang.)
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. globenewswire.com 2025-03-17 09:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Present at Upcoming March Investor Conferences SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com 2025-02-26 09:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. globenewswire.com 2025-02-21 09:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Participate in Upcoming February Investor Conferences SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com 2025-02-05 09:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [ 212 Pb]VMT-α-NET [ 212 Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Cohorts 1 and 2 who previously experienced stable disease remain in stable disease SEATTLE, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET that are being presented as a poster presentation at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) taking place January 23-25, 2025 in San Francisco, CA. globenewswire.com 2025-01-24 09:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). globenewswire.com 2025-01-06 10:00:00 Czytaj oryginał (ang.)
Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM Perspective Therapeutics' radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company's theranostics approach that delivers radiation directly to tumors. This can potentially minimize healthy tissue damage, and it has already had promising early results in neuroendocrine tumors. Currently, CATX's main candidates are VMT01 for melanoma and VMT-α-NET for neuroendocrine tumors. They're both in Phase 1/2 trials, and VMT01 has Fast Track Designation. seekingalpha.com 2024-12-23 13:13:44 Czytaj oryginał (ang.)
Perspective Therapeutics: Definitely Not Looking Overvalued Now Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to continue research for years, despite current market skepticism and a significant drop in valuation. Alpha emitter PRRT offers a potentially safer alternative to beta emitters, but faces challenges in manufacturing, handling, and market uptake. seekingalpha.com 2024-12-20 18:16:23 Czytaj oryginał (ang.)
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com 2024-11-27 09:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced initial results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET that are being presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. globenewswire.com 2024-11-21 09:15:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. globenewswire.com 2024-11-15 18:08:00 Czytaj oryginał (ang.)
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc . (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced third quarter financial results for the period ended September 30, 2024. globenewswire.com 2024-11-12 18:05:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com 2024-10-29 09:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company's radiopharmaceutical programs being presented at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM") held in Hamburg, Germany, from October 19-23, 2024. globenewswire.com 2024-10-23 11:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from its second manufacturing facility for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. globenewswire.com 2024-10-16 11:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 are being presented at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana. globenewswire.com 2024-10-11 12:30:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana. globenewswire.com 2024-10-10 21:14:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel discussions and company presentations at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit in New York, NY on October 8, 2024 and the JonesResearch Virtual Radiopharma Day on October 29, 2024. globenewswire.com 2024-10-07 11:00:00 Czytaj oryginał (ang.)
Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of 2024. The global melanoma market is expected to grow to $13.11 billion by 2029. Clinical supply agreement made with Bristol-Myers Squibb for use of Opdivo as a checkpoint inhibitor to be combined with VMT-01 to target patients with MC1R-positive metastatic melanoma. seekingalpha.com 2024-10-02 19:11:45 Czytaj oryginał (ang.)
Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2 Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close of $12.63. gurufocus.com 2024-10-02 16:10:44 Czytaj oryginał (ang.)
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (“EANM”), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the Company's other assets, including results based on investigator-initiated use of certain of those assets, will also be made at EANM. globenewswire.com 2024-09-30 11:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or “MC1R,” is a protein that can be overexpressed in metastatic melanoma. globenewswire.com 2024-09-05 11:00:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com 2024-08-28 11:00:00 Czytaj oryginał (ang.)
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year? Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year. zacks.com 2024-08-13 14:40:51 Czytaj oryginał (ang.)
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced second quarter financial results for the period ended June 30, 2024. globenewswire.com 2024-08-12 20:05:00 Czytaj oryginał (ang.)
Perspective Therapeutics to Participate at Upcoming Investor Conferences in August SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as noted. globenewswire.com 2024-07-30 11:00:00 Czytaj oryginał (ang.)